Biosimilar User Fees: Industry, FDA Tussle On Ramp-Up Speed For Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry says performance goals should not be phased-in, but FDA says it does not have enough money to be full-strength at launch.